EUVIMEDEUVIMED entdecken
Leserbrief

Upadacitinib shows efficacy in Netherton syndrome with poor response to Dupilumab

Hui Li iD, Jianbo Wang

The Journal of Dermatology · 2025-02 · 52 (2)

DOI: 10.1111/1346-8138.17461 ↗

Kurz gefasst

Leserbrief in der Zeitschrift The Journal of Dermatology, online erschienen am 20.09.2024. Verfasst von Hui Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 4 Literaturangaben. Gefördert von: Natural Science Foundation of Henan Province(202300410386).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Dermatology, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
  • Department of Dermatology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, China.

ORCID-Profile: Hui Li

Förderung

  • Natural Science Foundation of Henan Province(202300410386)

Zitieren

APA

Li, H., & Wang, J. (2025). Upadacitinib shows efficacy in Netherton syndrome with poor response to Dupilumab. The Journal of Dermatology, 52(2). https://doi.org/10.1111/1346-8138.17461

Vancouver

Li H, Wang J. Upadacitinib shows efficacy in Netherton syndrome with poor response to Dupilumab. The Journal of Dermatology. 2025;52(2). doi:10.1111/1346-8138.17461

BibTeX
@article{Li2025,
  author = {Li, Hui and Wang, Jianbo},
  title = {Upadacitinib shows efficacy in Netherton syndrome with poor response to Dupilumab},
  journal = {The Journal of Dermatology},
  year = {2025},
  volume = {52},
  number = {2},
  doi = {10.1111/1346-8138.17461}
}
Kostenlos starten →